Stock News

29.45% to Target, Canaccord Genuity Reconfirms “Buy” Rating for Karyopharm Therapeutics (KPTI) Stock; Metals USA Has 0.74 Sentiment

Murphy USA Inc. (NYSE:MUSA) Logo

They currently have a $24.0000 TP on Karyopharm Therapeutics (NASDAQ:KPTI). Canaccord Genuity’s target would suggest a potential upside of 29.45% from the company’s previous close. This was released in a note on 15 May.

Metals USA Inc (MUSA) investors sentiment increased to 0.74 in Q4 2017. It’s up 0.02, from 0.72 in 2017Q3. The ratio is more positive, as 90 funds increased and started new holdings, while 122 decreased and sold their holdings in Metals USA Inc. The funds in our database now have: 29.87 million shares, down from 32.81 million shares in 2017Q3. Also, the number of funds holding Metals USA Inc in top ten holdings decreased from 4 to 2 for a decrease of 2. Sold All: 23 Reduced: 99 Increased: 45 New Position: 45.

The stock increased 0.23% or $0.16 during the last trading session, reaching $69.47. About 315,697 shares traded. Murphy USA Inc. (MUSA) has risen 1.66% since May 17, 2017 and is uptrending. It has underperformed by 9.89% the S&P500.

Murphy USA Inc. operates a chain of retail stores in the United States. The company has market cap of $2.31 billion. The companyÂ’s retail stores offer motor fuel products and convenience merchandise. It has a 10.25 P/E ratio. As of January 3, 2017, it operated approximately 1,400 retail stores located primarily in the Southwest, Southeast, and Midwest United States.

Another recent and important Murphy USA Inc. (NYSE:MUSA) news was published by Globenewswire.com which published an article titled: “Murphy USA Inc. Reports First Quarter 2018 Results” on May 01, 2018.

Analysts await Murphy USA Inc. (NYSE:MUSA) to report earnings on August, 1. They expect $1.12 EPS, down 25.83% or $0.39 from last year’s $1.51 per share. MUSA’s profit will be $37.23M for 15.51 P/E if the $1.12 EPS becomes a reality. After $0.12 actual EPS reported by Murphy USA Inc. for the previous quarter, Wall Street now forecasts 833.33% EPS growth.

Southernsun Asset Management Llc holds 5.3% of its portfolio in Murphy USA Inc. for 2.59 million shares. Cutter & Co Brokerage Inc. owns 70,147 shares or 2.32% of their US portfolio. Moreover, Signature Financial Management Inc. has 1.79% invested in the company for 82,443 shares. The Connecticut-based Iridian Asset Management Llc Ct has invested 1.38% in the stock. Horrell Capital Management Inc., a Arkansas-based fund reported 28,641 shares.

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It turned negative, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Raymond James Associates stated it has 19,734 shares. Tiaa Cref Investment Mgmt has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 79,898 shares. Deutsche National Bank Ag invested in 188,373 shares or 0% of the stock. Tower Research Capital (Trc) owns 893 shares or 0% of their US portfolio. Moreover, Metropolitan Life Insurance Com New York has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 11,177 shares. Franklin Resources accumulated 3.34 million shares. Bancorporation Of America Corp De has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Thomas J Herzfeld Advisors, a Florida-based fund reported 1,500 shares. Wells Fargo And Co Mn accumulated 30,974 shares or 0% of the stock. Credit Suisse Ag accumulated 0% or 40,053 shares. Mutual Of America Management reported 0.02% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Citadel Ltd Llc stated it has 54,308 shares. Art Advisors Ltd Co reported 0.01% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Schwab Charles Inv Mngmt holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 150,289 shares. Proshare Advsrs Ltd Limited Liability Company stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.12 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin??s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.33’s average target is 31.23% above currents $18.54 stock price. Karyopharm Therapeutics Inc. had 37 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 15. JP Morgan maintained the stock with “Overweight” rating in Tuesday, April 10 report. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Monday, March 12 by Canaccord Genuity. The rating was maintained by Leerink Swann with “Buy” on Tuesday, May 1. The rating was initiated by Robert W. Baird on Tuesday, June 28 with “Outperform”. As per Thursday, August 18, the company rating was initiated by H.C. Wainwright. On Thursday, November 2 the stock rating was maintained by RBC Capital Markets with “Buy”. The rating was maintained by JP Morgan with “Overweight” on Monday, March 14. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Overweight” rating given on Wednesday, September 2 by JP Morgan. The company was downgraded on Tuesday, March 15 by Bank of America.

The stock increased 0.65% or $0.12 during the last trading session, reaching $18.54. About 504,600 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 17, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on August, 14. They expect $-0.73 earnings per share, down 14.06% or $0.09 from last year’s $-0.64 per share. After $-0.78 actual earnings per share reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -6.41% EPS growth.

Murphy USA Inc. (NYSE:MUSA) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *